News Snapshot:
Vivo Capital's portfolio companies include WuXi AppTec, one of Asia's largest pharmaceutical R&D platforms. (Captured images from Wuxiapptec and Vivo Capital website) EUDORA WANG, DealStreetAsia June 1, 2022 14:49 JST | Hong Kong Copy Copied HONG KONG -- Vivo Capital, a global health care investment company that has backed Chinese companies such as medical-tech platform WuXi AppTec, has held the first closing of a new yuan-denominated fund at 4 billion yuan ($600 million), with a target of eventually raising about 10 billion yuan. Read Next
